Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

newbulloh2 Dec. 5 at 4:42 AM

$JSPR how is this for missinformed securities fraud..

0 · Reply

_GoldenLairTrading Dec. 5 at 12:12 AM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $GGB $JFBR $JANX $TU $JSPR ;

0 · Reply

GoldenSteers__ Dec. 4 at 9:10 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $DNA $SMLR $JSPR $JANX Rage

0 · Reply

stocktttt Dec. 4 at 5:51 PM

$JSPR need PR to bring up volume, not much will happen today.

1 · Reply

R3ady2 Dec. 4 at 4:24 PM

$JSPR break through a his 1.80 wall and the next resistance is 1.90 followed by 2.00. If break of 2.00 today, we shall see 2.20 retest.

0 · Reply

R3ady2 Dec. 4 at 4:15 PM

$JSPR as this keeps moving up, we should get more eyes on and the push will continue. Showing really great strength

0 · Reply

HodlQueen22 Dec. 4 at 3:37 PM

$JSPR trial data soon …the shorts had their time…

0 · Reply

STAFWINS Dec. 4 at 3:29 PM

$JSPR This is a great company - my third cousin sister's ex-husband works here.

1 · Reply

NIVOLOCO Dec. 4 at 3:20 PM

$JSPR ☝️

0 · Reply

newbulloh2 Dec. 4 at 3:07 PM

$JSPR short 1.74

3 · Reply

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript

Dec 2, 2025, 7:00 AM EST - 2 days ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 3 days ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 12 days ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 17 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 24 days ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 24 days ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 27 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 7 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 2 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 2 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 2 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 5 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 5 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 5 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 6 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 7 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 9 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 10 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 10 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 11 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 11 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

newbulloh2 Dec. 5 at 4:42 AM

$JSPR how is this for missinformed securities fraud..

0 · Reply

_GoldenLairTrading Dec. 5 at 12:12 AM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $GGB $JFBR $JANX $TU $JSPR ;

0 · Reply

GoldenSteers__ Dec. 4 at 9:10 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $DNA $SMLR $JSPR $JANX Rage

0 · Reply

stocktttt Dec. 4 at 5:51 PM

$JSPR need PR to bring up volume, not much will happen today.

1 · Reply

R3ady2 Dec. 4 at 4:24 PM

$JSPR break through a his 1.80 wall and the next resistance is 1.90 followed by 2.00. If break of 2.00 today, we shall see 2.20 retest.

0 · Reply

R3ady2 Dec. 4 at 4:15 PM

$JSPR as this keeps moving up, we should get more eyes on and the push will continue. Showing really great strength

0 · Reply

HodlQueen22 Dec. 4 at 3:37 PM

$JSPR trial data soon …the shorts had their time…

0 · Reply

STAFWINS Dec. 4 at 3:29 PM

$JSPR This is a great company - my third cousin sister's ex-husband works here.

1 · Reply

NIVOLOCO Dec. 4 at 3:20 PM

$JSPR ☝️

0 · Reply

newbulloh2 Dec. 4 at 3:07 PM

$JSPR short 1.74

3 · Reply

newbulloh2 Dec. 4 at 1:15 PM

$JSPR break 1 .56 and drop baby!!! Lesss go

0 · Reply

topstockalerts Dec. 4 at 12:42 PM

Pre Market Top Gainers $PLRZ $FTEL $TAOP $JSPR $MDB

1 · Reply

Steve1545 Dec. 3 at 9:05 PM

$JSPR ha smells like dead meat in here. Bullish cldx

0 · Reply

MrCodyHUN Dec. 3 at 9:03 PM

$JSPR Impressive rebound from the start of the day.

0 · Reply

robert896 Dec. 3 at 9:01 PM

$JSPR you can see the movement. That’s a move right there lol

0 · Reply

BiotechValues Dec. 3 at 8:46 PM

So $JSPR will have ~50 patients worth of data coming in Jan. With ~40 of which from the OLE study shown below:

1 · Reply

BiotechValues Dec. 3 at 8:34 PM

$JSPR all comes down to January data. You can tell they plan to deliver a win over $CLDX (that is the bar). Equal or better efficacy and a better safety profile

1 · Reply

DarkOrb Dec. 3 at 8:28 PM

$JSPR Found the replay - he didn't say much else before the conference ended. Just that the catalyst was the data early next year. He didn't explain what their plans are regarding raising more cash. Absolutely pathetic management. This guy should be running a university research lab not a public for-profit company. Stock down 95%+ YTD, trading at all time lows and he can't be bothered to talk about business plans or their incineration of investors. Well done Ron. You're absolutely pathetic.

1 · Reply

Stmkr Dec. 3 at 8:24 PM

$JSPR They cant even do a propel call...

0 · Reply

Stmkr Dec. 3 at 8:23 PM

$JSPR Audio cut???

1 · Reply

robert896 Dec. 3 at 8:16 PM

$JSPR better get in lol

0 · Reply

RunnerSignals Dec. 3 at 8:16 PM

$JSPR Volume hot could be shorts covering. Watch overnight to see if bulls keep the punch

1 · Reply

Market Cap	46.17M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,968,200
Avg Vol	1,742,430
Day's Range	N/A - N/A
Shares Out	27.98M
Stochastic %K	46%
Beta	3.06
Analysts	Strong Sell
Price Target	$12.67